Biofilm Formation by the Fungal PathogenCandida albicans: Development, Architecture, and Drug Resistance

By J. Chandra, D. Kuhn, P. Mukherjee, L. Hoyer, T. McCormick, M. Ghannoum. Journal of Bacteriology, 2001

1,670 citations recorded by the source corpus.

Subfields: Food Science, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5f936fc6a6eca71bfecadab7599c5ea99fe548d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

In Infectious Diseases

In Molecular Biology

Citations in the corpus

GENETIC CONTROL OF CANDIDA ALBICANS BIOFILM DEVELOPMENT (2010, neutral): “albicans biofilm development to be viewed as a series of sequential step”
Candida albicans biofilms: development, regulation, and molecular mechanisms (2016, background): “The hyphae in biofilms contribute to the overall architectural stability of 283 the biofilm, and act as a support scaffold for yeast cells, pseudohyphae, other hyphae, 284 and other microbial cells in the context of polymicrobial biofilms (see below) [11,36].”
Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. (2013, background): “Availability to the inside of medical devices, such as central and peripheral catheters, haemodialysis and peritoneal dialysis units and intracardiac prosthetic valves, facilitates biofilm formation (Mukherjee & Chandra, 2004; Chandra et al., 2001; Ramage et al., 2005).”
Multidrug tolerance of biofilms and persister cells. (2008, background): “The biofilm forms when single cells attach to a surface and grow into microcolonies, which then merge and produce a complex 3D structure that is held together by hyphae and an exopolymer matrix ( Chandra et al. 2001 ).”
Candida Biofilms: an Update (2005, methodology): “Biofilms have also been recovered directly from clinical samples and visualized using different microscopy techniques (17, 74, 82).”
Candida Infections of the Genitourinary Tract (2010, background): “fungal attachment, growth, and biofilm formation (49, 140).”
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “Catheters, like other medical devices, can serve as a substrate for Candida biofilm infection, which exhibits a drug-resistant phenotype [60, 61], necessitating biofilm extirpation for treatment success [62, 63].”
Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. (2012, background): “…shift, and while C. albicans remains the most common causative agent, its relative incidence in infection is declining with the increasing prevalence of other species such as C. glabrata, C. tropicalis and C. parapsilosis (Chandra et al., 2001; Colombo et al., 2003; Bassetti et al., 2006).”
Candida Infections of Medical Devices (2004, background): “Fully mature Candida biofilms have a mixture of morphological forms and consist of a dense network of yeasts, hyphae, and pseudohyphae in a matrix of polysaccharides (19), carbohydrate, protein, and unknown components (Fig.”
A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans (2012, background): “See also Figure S4. strain formed a biofilm with typical architecture and thickness (Chandra et al., 2001; Douglas, 2003; Nobile and Mitchell, 2005) of 250 mm in depth, containing both round budding yeast-form cells adjacent to the substrate and hyphal cells extending throughout the biofilm (Figure…”
Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins (2002, background): “As predicted by earlier work (13, 14, 21, 29), our model C.”